Daiichi Sankyo Optimistically Ramping Up For Prasugrel Launch
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo CEO Takashi Shoda acknowledged during the company's third quarter results call that the delay in U.S. FDA approval of Effient (prasugrel), a novel platelet inhibitor that the company filed jointly with Eli Lilly in December 2007, has negatively affected the company net sales forecast
You may also be interested in...
Daiichi Sankyo/Lilly's Prasugrel Clears FDA
WASHINGTON - U.S. FDA is showing no evidence of summer doldrums - the agency has approved Daiichi Sankyo/Lilly's oral platelet inhibitor Effient (prasugrel)
Daiichi Sankyo/Lilly's Prasugrel Clears FDA
WASHINGTON - U.S. FDA is showing no evidence of summer doldrums - the agency has approved Daiichi Sankyo/Lilly's oral platelet inhibitor Effient (prasugrel)
Daiichi Sankyo’s Infringement Lawsuits Highlight Japan’s Generic Drug Tug-Of-War
Daiichi Sankyo waged patent infringement war against generic drug makers with lawsuits registered in two Japanese district courts March 23. The antibacterial drug Cravit (levofloxacin) lies at the center of the litigation brought by Daiichi Sankyo